The Indian Pharmaceutical Production Intensified The Chains Worth

In 2013, there were 4,655 pharmaceutical manufacturing plants in India, employing over 345 thousand workers.

Whether eastern-based medicine or western medicine, there is a multitude of so-called healing modalities. A plethora of industries is available to get their share of the huge financial pie. The pharmaceutical industry is one of the

There are advantages of starting a pharmaceutical firm in India. It has emerged from being an enzyme-producing firm to a biotech powerhouse under the guidance of Ms Kiran M. Shaw. They have a well-established pharmaceutical industry that has been growing since 1947. After the purchase of Hindustan Antibiotics Ltd. and India Drug and Pharmaceuticals Ltd. they were able to compete with the MNC’s (Multi National Corporaton) from overseas (Kalegaonkar, Locke, Lehrich, 2008, p. 2). In the beginning the pharmaceutical industry saw substantial growth. “By the beginning of the 21st century, over 20,000 pharmaceutical companies were operating in India” (Kalegaonkar, Locke, Lehrich, 2008, p. 2). “The pharmaceutical industry in India is ranked third

The biggest challenge faced by a foreign company is that the local manufacturers will copy their product in a matter of weeks and mass-produce and distribute it throughout the country at a very cost effective rate. Another problem can be the strict rule of Chinese food and drug authority’s strict rule regarding the registration of devices.

We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.

The pharmaceutical industry has shown remarkable structural stability as majority of its key players have been in existence for almost a century now. However, it has not been an exception to unpredictable times of the 21st century as it is grappling with quite a number of challenges. The most urgent issues include termination of manufacturers’ rights, importation risks, pricing problems and the infiltration of counterfeit drugs, the cost of R&D and political and administrative constraints notwithstanding. Most of these challenges have existed over a long period and the rate at which they are escalating presents a big threat to the industry.

In the world the main hub of pharmaceutical industry are in United Kingdom, USA. New Zealand is far away located from these countries and has a population of 4.4 million and has got less number of pharmaceutical industries. The statistics figure show that there were only two compounds developed during 2001 but due to increased in the government funds from $16.3 million in the year 2000-2001 to $43.1 million in the year 2006-2007 the number increased to 12. The success and profit of a pharmaceutical industry depends on the research of molecule, its efficiency and the cost in the market. The main factor for the gradual decline in the profit of the pharmaceutical industry was decrease in the production and increase in the cost of the drug. As a result this industry is going to build a new method that includes the developing alliance with the smaller companies which will help in reducing the manufacturing cost. (Lockhart, 2012).

The pharmaceutical industry is today one of the most lucrative and prominent world business sectors. It consists of numerous public and private organizations dedicated to the detection, development, creation and marketing of medicines for human and animal health. Its foundation is the research and development for medicinal chemicals to prevent or treat innumerable diseases and disarrays. The pharmaceutical industry mainstream of production corresponds to vaccines. Most pharmaceutical companies experience international character and maintain subsidiaries in several nations. The pharmaceutical sector is technologically advanced, which gives employment to many college graduates with MBA degrees, biologists, biochemists, chemists, pharmacists, and physicians. These professionals perfom in the functional regions of production, quality control, research and development, marketing, human resources, and general administration. The majority of jobs within the

In retrospect, Chinese companies invested small portion in R&D, typically 2% of sales by far away from Indian companies’ 7.7% (Grace, 2004). Overall, Indian firms are supported by R&D programs and have well positioned themselves in the domestic market so that more intense competition will be confronted in Indian pharmaceuticals industry. Another weakness when exporting to India is that India is among the lowest in the world in terms of per capita consumption of pharmaceuticals, with $4.50 compared to $13 in China (Greene, 2007). Under those conditions, more promising pharmaceuticals market can be expected in China than in India. Furthermore, with the rising number of affluent Chinese, diseases such as diabetes, cardiovascular diseases and cancer all shows the growing trend, offering a huge market demand for drug development (kermani, 2008). The huge market demands as well as less competition make China an attractive market for pharmaceuticals industry.

* 1. Case Study Kramer Pharmaceuticals, Inc. Presented by Debi Prasad Bagria Kishor Chandwani Nandini Mudgil Mrinmoy Kanti Das Rahul Agarwal Ritesh Kumar Singh

About a third of the total world population has no access to essential drugs, and more than half of this group lives in poor regions of Asia and Africa (Sterckx 21). There are many factors that affect the accessibility of drugs to patients in developing countries, one of them being the patent system. Patent is an intellectual property right that relates to innovations and grants exclusive ownership right of an invention to a patentee, and protects the patented product to reproduction, using, selling, importing, or process producing the patented product (John and Wendy 1). This paper explores the patent law in India in relation to its legal justifications(domestic and international), as well as the ethical considerations in relation to patent medical drugs.

It built a new factory in India in 2010, which is expected to be the hub for low-cost generic drugs production and to take over high-cost production in Japan. It also established Eisai Knowledge Centre India to create a future global hub for ensuring a stable supply of the drug and innovate in the Active Pharmaceutical Ingredients formulation (Eisai, 2009). In consequence, Eisai must close down its production facility in Misato Japan, after they transfer the production skills and know-how to India (Eisai,

The Indian pharmaceutical industry has become the third largest producer in the world in terms of volumes and is poised to grow into an industry of $20 billion in 2015 from the current turnover of $12 billion. In terms of value India still stands at number 14 in the

The profession of Pharmacy is not only the science of practicing of preparation and dispensing of medicinal drugs but also providing quality of life to the individuals/patients.pharmacists are one of the health care providers who act as mediators between physicians and the patients. The profession of pharmacy is well managed globally specially in the developed countries. Since the pharmacists are the only professionals who manufacture the medicines and have an in-depth knowledge about the drugs, they should be given treatment rights on par with the physicians. The careers of pharmacists are diverse if they are well recognized. Hence the government of India should take proper steps to manage the pharmaceutical industry and show them better career prospects.

The concept of product patent for pharmaceutical products is likely to make life saving medicine beyond the reach of the poor and deprived section of the society around the world.